Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Passeron T, Prajapati VH, Sivamani RK, Ezzedine K, van Geel N, Hamzavi I, Pandya AG, Rosmarin D, Xiang L, Suzuki T, Desai S, Rashighi M, Suravaram S, Fish I, Hu X, Wu X, Wang M, Yu Y, Soliman AM, Camp HS, Teixeira HD, Patterson S, Schlosser BJ, Seneschal J

Open source

DOI: 10.1016/s0140-6736(26)00896-2
Published: 2026 Aug 15
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00896-2,
  title = {Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.},
  author = {Passeron T and Prajapati VH and Sivamani RK and Ezzedine K and van Geel N and Hamzavi I and Pandya AG and Rosmarin D and Xiang L and Suzuki T and Desai S and Rashighi M and Suravaram S and Fish I and Hu X and Wu X and Wang M and Yu Y and Soliman AM and Camp HS and Teixeira HD and Patterson S and Schlosser BJ and Seneschal J},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)00896-2},
  url = {https://doi.org/10.1016/s0140-6736(26)00896-2}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.
AU  - Passeron T
AU  - Prajapati VH
AU  - Sivamani RK
AU  - Ezzedine K
AU  - van Geel N
AU  - Hamzavi I
AU  - Pandya AG
AU  - Rosmarin D
AU  - Xiang L
AU  - Suzuki T
AU  - Desai S
AU  - Rashighi M
AU  - Suravaram S
AU  - Fish I
AU  - Hu X
AU  - Wu X
AU  - Wang M
AU  - Yu Y
AU  - Soliman AM
AU  - Camp HS
AU  - Teixeira HD
AU  - Patterson S
AU  - Schlosser BJ
AU  - Seneschal J
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)00896-2
UR  - https://doi.org/10.1016/s0140-6736(26)00896-2
ER  -

APA

T, P., VH, P., RK, S., K, E., N, V. G., I, H., AG, P., D, R., L, X., T, S., S, D., M, R., S, S., I, F., X, H., X, W., M, W., Y, Y., AM, S., HS, C., HD, T., S, P., BJ, S., & J, S. (2026). Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00896-2

Source records

pubmed · retrieved 2026-09-26T03:23:33.872Z